phrykt

ImmunityBio, Inc. (IBRX): who owns it and who trades it

As of Nov 16, 2026, IBRX insiders reported 16 open-market sales worth $9.5M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Barry J. Simon (Director), with $4.4M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling ImmunityBio

From the latest filings

Overall: more buying than selling. Congress mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IBRX

402 funds and institutions reported IBRX shares worth $1.8B at the end of Q2 2026, about 20% of the company. The largest holder is BlackRock, Inc. with 3.3%.

Funds and institutions (13F) 20%Everyone else 80%

10 largest owners, by share of the company

BlackRock, Inc.3.3%
State Street Corp2.0%
Vanguard Portfolio Management LLC1.7%
Vanguard Capital Management LLC1.5%
D. E. Shaw & Co., Inc.1.1%
Two Sigma Investments, LP1.1%
Geode Capital Management, LLC0.9%
Millennium Management LLC0.5%
Northern Trust Corp0.3%
Morgan Stanley0.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.34.08M3.25%$298M+29%
State Street Corp21.40M2.04%$187M+21%
Vanguard Portfolio Management LLC17.86M1.71%$156M+9%
Vanguard Capital Management LLC15.69M1.50%$137M+4%
D. E. Shaw & Co., Inc.11.55M1.10%$101M-8%
Two Sigma Investments, LP11.10M1.06%$97.2M+153%
Geode Capital Management, LLC9.85M0.94%$86.2M+23%
Millennium Management LLC5.58M0.53%$48.9M+293%
Northern Trust Corp3.57M0.34%$31.2M+42%
Morgan Stanley3.43M0.33%$30.1M-15%
Goldman Sachs Group Inc3.23M0.31%$28.3M-0%
UBS Group AG3.20M0.31%$28M+9%
Charles Schwab Investment Management Inc2.89M0.28%$25.3M+17%
Sixth Street Partners Management Company, L.P.2.89M0.28%$25.3M–
Woodline Partners LP2.50M0.24%$21.9M-27%
SEB Asset Management AB2.45M0.23%$21.4MNo change
Vanguard Fiduciary Trust Co2.41M0.23%$21.1M+14%
Bank of America Corp2.18M0.21%$19.1M-11%
Voloridge Investment Management, LLC1.72M0.16%$15.1M-41%
Federated Hermes, Inc.1.71M0.16%$15M+24%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IBRX insiders reported $0 of open-market purchases and $9.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$9.5M
16 trades, 3 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Oct 5, 2026
Filed Oct 6, 2026

Purchases and sales by month

$2.9M$2.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 5, 2026Barry J. SimonDirectorSale plan25,000$10.75$269KForm 4
Oct 2, 2026Cheryl CohenDirectorSale plan81,056$10.50$851KForm 4
Jul 2, 2026Cheryl CohenDirectorSale plan131,210$9.50$1.2MForm 4
Jul 1, 2026Christobel SeleckyDirectorSale plan159,478$9.02$1.4MForm 4
Jun 30, 2026Christobel SeleckyDirectorSale plan1,000$9.00$9KForm 4
Jun 29, 2026Christobel SeleckyDirectorSale plan95,722$9.01$862KForm 4
Jun 24, 2026Barry J. SimonDirectorSale plan25,000$7.88$197KForm 4
Jun 4, 2026Barry J. SimonDirectorSale plan23,033$7.18$165KForm 4
Feb 24, 2026Barry J. SimonDirectorSale plan75,000$12.01$901KForm 4
Feb 23, 2026Christobel SeleckyDirectorSale plan25,000$10.00$250KForm 4
Feb 23, 2026Barry J. SimonDirectorSale plan165,000$10.25$1.7MForm 4
Feb 20, 2026Barry J. SimonDirectorSale plan10,000$9.25$92.5KForm 4
Jan 20, 2026Barry J. SimonDirectorSale plan75,000$7.88$591KForm 4
Jan 20, 2026Barry J. SimonDirectorSale plan76,967$6.54$503KForm 4
Jan 20, 2026Christobel SeleckyDirectorSale plan25,000$7.51$188KForm 4
Jan 16, 2026Christobel SeleckyDirectorSale plan50,000$5.00$250KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Barry J. SimonDirector–$4.4MOct 5, 2026
Christobel SeleckyDirector–$3MJul 1, 2026
Cheryl CohenDirector–$2.1MOct 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IBRX short interest

High short interest. 11.9% of IBRX shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 5%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 126.08M IBRX shares were sold short, 11.9% of the shares outstanding, up 2.6% from the report before. At the average daily volume of 11.70M shares, buying them all back would take about 10.8 trading days (days to cover).

Shares short, % of all shares

11.9%May 15Oct 3013.1%

Days to cover

10.8May 15Oct 3017.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026126.08M11.90%+3%11.70M10.8
Oct 15, 2026122.95M11.60%-1%17.19M7.2
Sep 30, 2026124.09M11.71%-1%13.97M8.9
Sep 15, 2026125.41M11.83%-0%7.91M15.9
Aug 31, 2026125.64M11.85%-1%8.51M14.8
Aug 14, 2026127.50M12.03%-1%8.26M15.4
Jul 31, 2026129.00M12.17%-4%8.90M14.5
Jul 15, 2026134.40M12.83%+2%11.27M11.9
Jun 30, 2026131.83M12.59%-2%15.22M8.7
Jun 15, 2026135.15M12.90%+2%11.31M11.9
May 29, 2026132.14M12.62%-0%17.30M7.6
May 15, 2026132.75M12.68%-4%12.57M10.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded IBRX

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 0 sales of IBRX. The latest was a purchase by Lisa C. McClain on Sep 30, 2026, reported Oct 12, 2026.

Purchases 2Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 30, 2026Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseOct 12, 2026Report
Sep 28, 2026Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseOct 12, 2026Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

ImmunityBio company events

ImmunityBio filed 19 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Nov 9, 2026AnnouncementShared information with investors. Filing
  3. Oct 14, 2026AnnouncementShared information with investors. Filing
  4. Aug 4, 2026ResultsReleased financial results. Filing
  5. Jul 30, 2026AnnouncementShared information with investors. Filing
  6. Jun 10, 2026VoteReported shareholder vote results. Filing
  7. May 18, 2026AgreementImmunityBio, Inc., a Delaware corporation, entered into an exclusive development and supply agreement with Japan BCG Laboratory, a Japanese corporation. Filing
  8. May 7, 2026ResultsReleased financial results. Filing
  9. Apr 9, 2026ResultsReleased financial results. Filing
  10. Apr 6, 2026AnnouncementShared information with investors. Filing
  11. Mar 31, 2026AgreementImmunityBio, Inc. entered into a Second Amendment to Revenue Interest Purchase Agreement by and among the Company, the guarantors party thereto, the purchasers party thereto and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers, which amends that certain Revenue… Filing
  12. Feb 23, 2026ResultsReleased financial results. Filing
  13. Feb 18, 2026AnnouncementImmunityBio, Inc. issued a press release announcing that the Company has received authorization from the European Commission for ANKTIVA ® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, which expands global access of our product to 33 countries. Filing
  14. Jan 26, 2026AgreementImmunityBio, Inc. entered into a letter amendment to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million, by and among the Company and Nant Capital, LLC, an entity affiliated with Dr. Patrick… Filing
  15. Jan 15, 2026ResultsReleased financial results. Filing
  16. Jan 14, 2026AnnouncementImmunityBio, Inc. issued press releases announcing that The Saudi Food and Drug Authority (SFDA) has granted accelerated approval of: • ANKTIVA ® for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer whose disease has… Filing
  17. Dec 29, 2025AgreementImmunityBio, Inc. entered into Amendment No. 1 to the Open Market Sale Agreement SM dated April 30, 2021, with Jefferies LLC relating to the sale and issuance of shares of its common stock, par value $0.0001 per share, from time to time through an “at the market” offering program under which the… Filing
  18. Dec 15, 2025LeadershipThe board of directors of ImmunityBio, Inc. appointed Bruce Wendel to the Board, effective as of December 12, 2025, with a term expiring at the Company’s 2026 annual meeting of stockholders. Filing
  19. Dec 12, 2025AnnouncementImmunityBio, Inc. issued a press release announcing certain regulatory updates. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ImmunityBio financials

Famous investors that hold IBRX

2 of the 50 well-known investors we track reported holding IBRX in their latest 13F filing. The largest position is Israel Englander's, worth $36M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.82M$36M0.0%-32%
Ken Griffin · Citadel AdvisorsQ3 2026717,776$6.8M0.0%+428%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about ImmunityBio, Inc. (IBRX) stock

Who owns the most IBRX stock?

The largest reported owner of ImmunityBio, Inc. (IBRX) is BlackRock, Inc., with 3.3% of the company. In total, 402 funds and institutions reported holding IBRX at the end of Q2 2026, together about 20% of the shares. See the largest owners.

Are IBRX insiders buying or selling?

In the last 12 months, IBRX insiders reported no open-market purchases and 16 sales worth $9.5M. The latest trade was on Oct 5, 2026. See every trade.

What is the short interest in IBRX?

As of Oct 30, 2026, 126.08M IBRX shares were sold short, 11.9% of the shares outstanding, up 2.6% from the report before. At the average daily volume of 11.70M shares, buying them all back would take about 10.8 trading days (days to cover). See the history.

Have members of Congress traded IBRX?

Yes. 1 member of Congress reported 2 purchases and 0 sales of IBRX since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.

Which famous investors hold IBRX?

2 of the 50 well-known investors we track reported IBRX in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $36M. See all holders.

Executive pay

ImmunityBio's chief executive was paid a total of $12.7M for the year ended Dec 31, 2025, up 16% from $11M the year before. In the last 12 months, ImmunityBio's executives and directors bought no stock on the open market and sold $9.5M.

Chief executive, total pay$12.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$5.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.